SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs.
about
SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs.Formulation optimization of a palm-based nanoemulsion system containing levodopa.Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability.Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule.Optimizing efficacy of Amphotericin B through nanomodification.Evaluation of Carbamazepine (CBZ) Supersaturatable Self-Microemulsifying (S-SMEDDS) Formulation In-vitro and In-vivo.Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system.Injectable lipid emulsions-advancements, opportunities and challenges.Lipid nanoparticles for the delivery of poorly water-soluble drugs.Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles.Factorial design applied to the optimization of lipid composition of topical antiherpetic nanoemulsions containing isoflavone genistein.Protein Adsorption Patterns and Analysis on IV Nanoemulsions-The Key Factor Determining the Organ Distribution.Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers.Formulation and evaluation of nimodipine-loaded lipid microspheres.Development and optimization of chemically stable lipid microspheres containing flunarizine.Lipid emulsions as a potential delivery system for ocular use of azithromycin.Preparation and evaluation of lyophilized liposome-encapsulated bufadienolides.Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution.A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres.Optimization of the Preparation Process for an Oral Phytantriol-Based Amphotericin B Cubosomes
P2860
Q33304020-F40A3D11-65E9-4C98-9333-1F4DBAE1C619Q36396516-476CB015-3E86-4003-8F09-E455AE762C98Q36442187-E360D754-E574-4FF1-A22B-05DB2ED0B52BQ36841497-2A3F3E29-9DB5-478E-925A-2396764D0C66Q37178176-882BADB9-C39B-4AA1-8402-E9ADCEA7D494Q37268140-4CB5A7C8-8DB7-47BB-9F77-C298A0300E49Q37597619-4052E21F-0653-410A-B575-DB711112EDB3Q37803157-29127582-45FE-4E2E-93F8-134730F7727DQ37805594-B309345A-A188-4F28-9AFB-296646BB2A1EQ38095485-78119ECB-1FB7-4431-96DD-E1DED6346C31Q41985084-A5DD33F5-7053-47DE-9732-4D3EC315FB6EQ42271492-D0B9817F-C65A-44FB-BD90-00A9DF06F188Q43263297-D8BF45F4-B7D5-41C1-9FF2-634CB6C7BD77Q44223055-3E09E98A-718E-4ABC-BA1B-656725604CBCQ45974658-1A65A7AF-E724-422F-AE45-87196A1FD204Q45998067-426F5F6C-AB6F-4537-B133-B5F2C73E6E0FQ46051646-5F7A4296-DC26-4D2E-8832-CC3EA9F3B1B7Q48161831-E847E7EE-0600-4FBB-AF3E-78D96440AFA9Q50084493-3B1A87CC-DD9B-47CE-A482-27F5946E3507Q51057965-64837286-7754-45D0-AB7B-11ADDD173A9AQ58691692-6601C6F7-0C5A-4EF7-BFC6-F882B13F09DF
P2860
SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
SolEmuls-novel technology for ...... ons with poorly soluble drugs.
@ast
SolEmuls-novel technology for ...... ons with poorly soluble drugs.
@en
type
label
SolEmuls-novel technology for ...... ons with poorly soluble drugs.
@ast
SolEmuls-novel technology for ...... ons with poorly soluble drugs.
@en
prefLabel
SolEmuls-novel technology for ...... ons with poorly soluble drugs.
@ast
SolEmuls-novel technology for ...... ons with poorly soluble drugs.
@en
P2093
P1476
SolEmuls-novel technology for ...... ons with poorly soluble drugs.
@en
P2093
P304
P356
10.1016/J.IJPHARM.2003.09.019
P407
P577
2004-01-01T00:00:00Z